1,412 results on '"Uemura, Hiroji"'
Search Results
102. A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
103. Predicting the mineral composition of ureteral stone using non-contrast computed tomography
104. Ten-year outcomes of I125 low-dose-rate brachytherapy for clinically localized prostate cancer: a single-institution experience in Japan
105. Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer
106. Corrigendum to “What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021” [Eur Urol 2022]
107. Safety and efficacy of apalutamide in Japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo‐controlled, phase III TITAN study
108. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021 (vol 82, pg 6, 2022)
109. Corrigendum to 'What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021' [Eur Urol 2022]
110. Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis
111. Evaluation of tumor genomic variants in Japanese patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide: Protocol of a phase 4 study (CUARTET).
112. Preferences and perceptions of patients with metastatic castration-resistant prostate cancer for treatments and biomarker testing: An international qualitative study.
113. A qualitative research study in Japan investigating patients’ experience with metastatic castration-resistant prostate cancer: from diagnosis to decision for Ra-223 treatment
114. aPKCλ/ι Promotes Growth of Prostate Cancer Cells in an Autocrine Manner through Transcriptional Activation of Interleukin-6
115. Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison
116. Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
117. PD34-09 EFFICACY OF PHYSICIAN'S CHOICE OF ENZALUTAMIDE OR ABIRATERONE IN THE CONTROL ARM OF PROFOUND
118. INITIAL NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) IS A PROGNOSTIC MARKER IN PENILE CANCER PATIENTS.: MP28-05
119. Low serum dehydroepiandrosterone examined by liquid chromatography-tandem mass spectrometry correlates with poor prognosis in hormone-naïve prostate cancer
120. Usefulness of perflubutane microbubble-enhanced ultrasound in imaging and detection of prostate cancer: phase II multicenter clinical trial
121. The neutrophil-to-lymphocyte ratio at the prostate-specific antigen nadir predicts the time to castration-resistant prostate cancer
122. Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration‐resistant prostate cancer: AFTERCAB study
123. Unmet needs in non-metastatic castration-resistant prostate cancer from the Japanese patient perspective: a discrete choice experiment
124. 不妊を契機に発見された多精巣症の1例
125. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer
126. Adipocyte-derived monocyte chemotactic protein-1 (MCP-1) promotes prostate cancer progression through the induction of MMP-2 activity
127. MP73-07 BONE MANAGEMENT OF PROSTATE CANCER: FRAX TOOL COMBINATION WITH BMD CAN REDUCE UNNECESSARY TREATMENT
128. MP58-01 NEUTOROPHIL-TO-LYMPHOCYTE RATIO (NLR) MIGHT BE A NEW PROGNOSIS MARKER IN BLADDER CANCER PATIENTS AFTER RADICAL CYSTECTOMY
129. MP45-04 ANDROGEN DEPRIVATION THERAPY PREVENTS RECURRENCE OF BLADDER CANCER
130. Alterations of p16 and p14ARF genes and their 9p21 locus in oral squamous cell carcinoma
131. A Phase 2 Trial of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer and without Prior Chemotherapy (JPN-201 Study)
132. A Phase 2 Study of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer Who Had Received Docetaxel-based Chemotherapy
133. Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer
134. Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial
135. Early ureteral catheter removal after ureteroscopic lithotripsy using ureteral access sheath
136. Changing to a loop-type ureteral stent decreases patients’ stent-related symptoms
137. Pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Updated analyses after one additional year of follow-up from cohorts 4 and 5 of the KEYNOTE-199 study.
138. Phase I/II study to evaluate the efficacy of TAS0313, a cancer peptide vaccine, combined with pembrolizumab for locally advanced or metastatic urothelial carcinoma.
139. Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone‐sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study
140. A higher De Ritis ratio (AST/ALT) is a risk factor for progression in high-risk non-muscle invasive bladder cancer
141. The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level
142. URETEROSCOPY-ASSISTED RETROGRADE NEPHROSTOMY; A 150 CASE EXPERIENCE: PD36-07
143. LOW SERUM DIHYDROTESTOSTERONE IS A POWERFUL PREDICTOR OF GLEASON SCORE 7-10 OF PROSTATE CANCER IN MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 3-10NG/ML: MP63-08
144. Enzalutamide plus androgen deprivation therapy (ADT) versus flutamide plus ADT in men with castration-resistant prostate cancer (CRPC): AFTERCAB.
145. Apalutamide and Overall Survival in Prostate Cancer
146. Bilateral Encrusted Metallic Stent Successfully Removed by Ureteroscopic Lithotripsy Using a Ho:YAG Laser in a Patient with Malignant Myeloma
147. Apalutamide for metastatic, castration‐sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double‐blind, placebo‐controlled phase 3 TITAN study
148. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
149. Molecular targeting therapy with angiotensin II receptor blocker for prostatic cancer
150. Additional file 1 of Shared decision making, physicians’ explanations, and treatment satisfaction: a cross-sectional survey of prostate cancer patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.